Japan’s 1st Hemophilia B Gene Therapy Up for Panel Review on Feb. 19
To read the full story
Related Article
REGULATORY
- Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
May 22, 2025
- MHLW Orders Label Revisions for Diuretics, Zolgensma
May 22, 2025
- LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
May 22, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…